The Medicines Company (MDCO) Receives Market Authorization Renewal For Angiox® (Bivalirudin) From The European Medicines Agency And The European Commission
7/7/2014 10:13:38 AM
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP), and the European Commission have granted market authorization renewal for Angiox® (bivalirudin) following a review of the latest clinical, safety, and efficacy data, as well as the Angiox risk management plan. The CHMP recommendation for the renewal of the marketing authorization for Angiox reconfirms its favorable risk-benefit profile.
Help employers find you! Check out all the jobs and post your resume.
comments powered by